Where does Emerald Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Emerald Therapeutics, Inc. ranks #28,666 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Emerald Therapeutics, Inc. hold?

Emerald Therapeutics, Inc. holds 9 US utility patents granted between 2015 and 2024, spanning 12 technology areas.

What is Emerald Therapeutics, Inc.'s Innovation Score?

Emerald Therapeutics, Inc. has an Innovation Score of 27.6 out of 100 (24th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Emerald Therapeutics, Inc. focus on?

Emerald Therapeutics, Inc.'s top technology area is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids) with 7 patents, ranking #132 of 896 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Emerald Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Emerald Therapeutics, Inc.'s recent grant velocity is -71% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Emerald Therapeutics, Inc.'s patents?

Emerald Therapeutics, Inc.'s patents average 8.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Emerald Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Emerald Therapeutics, Inc.

USPTO PatentsView assignee record - 9 granted patents across 12 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Emerald ranks #28,666 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 12 technology areas.

#28,666
of 49,997 US assignees by volume: 24th percentile
by Innovation Score (27.6/100): 8.6
avg claims per patent: -71%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R28666 · US Corporation #28,666 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #28,666/49,997
PHOTO-FINISH Elli & Nooli
CPC-FOCUS C07H · 12 areas
INNOV-THIN 27.6/100
CLAIMS-PAR 8.6 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -71% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Elli & Nooli, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Emerald’s 27.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (29%) Velocity 2.2 pts (8%) Breadth 12.2 pts (44%) Claim depth 5.1 pts (19%)

Qualcomm Incorporated · highest

85
Emerald Therapeutics · this assignee

28
3D Lighting… · lowest

7

What this shows Emerald's Innovation Score is 27.6/100 (24th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Emerald?

Each dot is one of Emerald’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Emerald’s own 8.6 claims/patent is at or below the 17.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Emerald vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Emerald's grants concentrate

Emerald Therapeutics, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 77.8% of grants classified under C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2015. By volume, Emerald sits between Elli & Nooli, LLC and EnE Holdings Ltd.

Emerald's three-year grant acceleration

Emerald Therapeutics, Inc. shows 1 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Elli & Nooli

9
Elopak Systems

9
Elwah

9
Embalajes Capsa S…

9
Emerging Compound…

9
Emery Oleochemica…

9
Empow Cyber Secur…

9
Ene Holdings

9
Emerald Therapeut… ◀

9

What this shows Emerald holds 9 patents at rank #28,691, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Emerald

By rank, the assignees closest to #28,691 in granted patent volume.

Leaders in C07H (Sugars)

Other assignees with the most granted patents in Emerald's primary technology class.

Emerald's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 24th percentile higher than 24% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Emerald Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	11.1%
2016	2	22.2%
2017	2	22.2%
2019	2	22.2%
2021	1	11.1%
2024	1	11.1%

Which technologies does Emerald Therapeutics, Inc. patent most?

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 7

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 6

G06N - Computing Arrangements Based ON Specific Computational Models 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 2

C07K - Peptides 2

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 1

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Emerald Therapeutics, Inc.'s patent record in context - here's where to go next.

Emerald Therapeutics, Inc.'s lead technology class is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids), 77.8% of its portfolio - see every assignee active in that class. Explore C07H
Ranked #28,666 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Emerald Therapeutics, Inc. against Elli & Nooli, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.